Drug-induced thyroid dysfunction by Geenen, Vincent
Vincent Geenen, MD, PhD 
Research director at F.S.R. of Belgium 
University Hospital of Liege & GIGA-I3 Immunoendocrinology 
 
Drug-induced thyroid dysfunction 
16 April 2016 
Thyroid iodide (I-)/iodine (I0) metabolism 
1. Synthesis of thyroglobulin in the ER and secretion by exocytosis. 
2. Na/I symporter pumps iodide (I-) into follicular cell. 
3. Pendrin-mediated passive transfer of I- in the follicular lumen. 
4. In the colloid, I- is oxidized to iodine (I0) by thyroid peroxidase.  
5. I0 iodinates TG on Tyr residues.  
6. By conjugation, adjacent Tyr residues are paired together.  
7. The entire complex re-enters the follicular cell by endocytosis.  
8. Proteolysis by various proteases liberates T4 and T3, which enter the blood. 
Iodine-containing compounds potentially 
associated with iodine-induced thyrotoxicosis (IIT) 
 
Dietary reference intake: 150 µg 
Tolerable upper intake level (adult): 1,100 µg/day 
Thyroid needs: 70 µg/day 
¨  Radiological contrast agents 
¨  Topical iodine preparations 
¨  Food components: algae, erythrosine, hamburger thyroiditis 
¨  Drugs: amiodarone, vitamins, expectorants, potassium iodide…  
Agents inhibiting thyroid hormone synthesis      
and/or secretion 
¨  Blockade of iodide transport into the thyroid (Na/I symporter):                        
Lithium, KI, perchlorate, bromide 
 
¨  Impairment of TG synthesis and iodotyrosine coupling:                                    
ATD, sulfonylureas, sulfonamides, ketoconazole 
e 
¨  Inhibitors of thyroid hormone secretion:                                                        
Lithium, iodide (in large doses) 
 
¨  Undefined or discussed mechanisms:                                          
phenylbutazone, thalidomide, interleukin-2, interferon, sunitinib, sorafenib  
Agents interfering with extra-thyroidal metabolism 
of thyroid hormones 
 


















Chemotherapy with tyrosine kinase inhibitors 
 
Induction of primary hypothyroidism or ì LT4 requirement  
¨  Sunitinib (renal cell carcinoma, imatinib-resistant GI stromal tumors, 
papillary thyroid cancer) 
       ± 40% of cases 
¨  Sorafenib (several solid tumors) 
      ± 25% of cases 
 
      Suggested mechanisms: 
 - Destructive thyroiditis through inhibition on VEGF receptor èLow iodine uptake and thyroid 
   volume shrinkage? 
 -  Antiperoxydase effect? 
                      - Interaction with retinoic acid receptor subtypes (Shu M et al. PLoS One 2016)? 




Highly effective in the long-term management of bipolar disorder. 
Induction of goiter (up to 60%) and hypothyroidism (up to 40%) 
 
Mechanisms still elusive: 
- Net positive intrathyroidal iodine balance (down-regulation of thyroid hormone secretion?) 
- Wolff-Chaikoff effect? 
- Autoimmunity not increased. 
- Direct toxic effect on thyroid (cases of self-limited thyrotoxicosis). 
 
Important message: 
The presence of previous thyroid disorders is almost never a 




Important class III antiarythmic drug (2 atoms iodine/molecule) 
Dailly dose of amiodarone (300 mg) – Half-life 40-60 days!  
= 111 mg iodine (10% available as inorganic) 
= 30-100x daily dose of inorganic iodine. 
 
Clinical thyroid disorders: 
1. Thyrotoxicosis (AIT, 2-12%) 
 Type I AIT: consequence of iodine load on pre-existing thyroid autonomy. 
 Type II AIT: destructive thyrotoxicosis by amiodarone or iodine in excess.  
 Differential diagnosis: I123 uptake and 99m Tc Sestamibi, nodules and low vascular flow, 
 and Ab to TSHR, TPO, Tg (Type I AIT) 
 Treatment of type I AIT: thionamides (but effect blunted by large iodine burden) 
 + potassium perchlorate (inhibitor of NA/I symporter) + amiodarone disruption. 
 Treatment of type II AIT: glucocorticoids, amiodarone disruption not obligatory. 
 
2. Hypothyroidism (AIH, 5-15%): preexistent or acquired inability to escape from 
 Wolff-Chaikoff effect. 
 
Drugs affecting thyroid hormone replacement 
therapy 
 
Drugs affecting thyroid hormone absorption 
LT4 absorption occurs in duodenum and jejunum and requires stomach acidity. 
è Antacids (proton-pump inhibitors), H2 receptor antagonists, CaCO3, 
aluminium hydroxyde, ferrous sulfate (direct binding of LT4),                                 
bile acid sequestrants 
 
Drugs altering thyroid hormone metabolism 
Activators of the cytP450 system: rifampicin, phenytoin, carbamazepine, 
barbiturates, imatinib (TK inhibitor) 
 
Estradiol per os 
Dose adjustment because of ì TBG  
 




v  Interleukin-2 (IL-2) 
v  Alemtuzumab 
v  Anti-retroviral therapy (HAART) 
 
Types of T-cell responses 
Interferon α (IFNα) 
Treatment of hepatitis C, and other infectious and malignant conditions          
(mainly carcinoids, breast cancer). 
Induction of autoimmunity up to 15-20% 
Transient, destructive thyrotoxicosis (50%) without secondary development of 
autoimmunity (≠ post-partum thyroiditis) 
 
Induction of thyroid dysfunction: 2-8% of cases. 
 - Most frequent: hypothyroidism (Hashimoto or type 2 autoimmune thyroiditis) 
 - Transient thyrotoxicosis (from inflammatory destructive thyroiditis) 
 - More rarely, induction of Graves’disease or Type 3 autoimmune thyroiditis  
 
Treatment 
 - Hypothyroidism: LT4 
 - Thyrotoxicosis: β-blockers 
 - Hyperthyroidism: recommendation for 131I or surgery (hepatic effects of ATD). 
 
Thyroiditis, inflammation and destruction of thyroid 
parenchyme in a patient treated with IFNαmet en 
Maiga et al., Rev Méd Liège 2015, 70: 390-394 
Interleukin-2 (IL-2) 
 
Treatment of melanoma and metastatic renal cell carcinoma. 
 
Induction of hypothyroidism (20-50% of cases) with anti-TPO, TG Abs. 
 
Sometimes, transient destructive thyrotoxicosis with T-cell infiltrate in thyroid but 




Beta-blockers for transient thyrotoxicosis. 
Alemtuzumab 
= humanized mAb to CD52, a glycosylphosphatidylinositol (GPI) low MW 
glycoprotein anchored and expressed at very high density in membrane of 
normal and malignant lymphoid B and T cells. 
Treatment of B and T cell malignancies and autoimmune diseases (rheumatoid 
arthritis but mainly relapsing-remitting multiple sclerosis/MS). 
Induction of cell destruction via activation of CDC and ADCC. 
Main adverse events:  
 - Wide immunosuppression and secondary infections. 
 - Immunogenicity of the drug! 
 - Autoimmune thrombocytopenia. 
 - Autoimmune glomerulonephritis. 
 - Autoimmune hypothyroidism. 
 - Induction of autoimmune hyperthyroidism (up to 30% of cases) with de novo Abs to TSHR. 
   MS patients are peculiarly susceptible (common locus in MS and Graves’: CD40). 
 
Mechanism: reconstitution of the immune system (after profound immune suppression and 
lymphopenia like during alemtuzumab treatment) with unbalanced expansion of self-
reactive T cells. 
 
Anti-retroviral therapy (HAART) 
Treatment of HIV-positive patients. 
 
Some studies suggest that HAART may precipitate Type 3 autoimmune thyroiditis 
(Graves’ disease) in predisposed subjects. 
Proposed mechanism: 
Reconstitution of the immune system (after profound immune suppression and 
lymphopenia like during alemtuzumab treatment) with unbalanced expansion of 
self-reactive T cells (see Alemtuzumab). 
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Thank you for your attention! 
